Talk Details · PDDS 2022

Drug Delivery to the Brain using Engineered Protein Capsules (EnPCs®)

Keynote · Day 1

Abstract

About this talk

The blood brain barrier (BBB) is both a blessing and a curse: On the one hand, the tightly connected endothelial cells covering the cerebral blood vessels protect the brain from harmful large molecules. On the other hand, they are the obstacle to treat severe central nerve system (CNS) diseases. The limiting factor is not the absence of active compounds, but to facilitate their passage through the BBB. To achieve this goal, NEUWAY Pharma GmbH develops a next-generation, proprietary CNS drug delivery platform technology enabling drug transport across the BBB for a broad spectrum of therapeutic compounds, such as small molecules, nucleic acids (incl. mRNA or plasmid DNA, oligonucleotides) or proteins (incl. antibodies). The cargo molecules are encapsulated in the lumen of biotechnologically manufactured and purified Engineered Protein Capsules (EnPCs®), which are derived from the shell of the common John Cunningham Virus (JCV) maintaining its CNS tropism. The resulting stable protein nanoparticles are very well characterized, stable, protect the cargo molecules against detrimental environmental effects such as degradation and overcome two physiological barriers, i.e. BBB and cell membrane of target cells.

Speaker

About the speaker

Victoria Demina

Victoria Demina

NEUWAY Pharma GmbH, Germany

View full speaker profile →

Join the PDDS 2027 delegation

Valencia · September 13–15, 2027 · Hybrid · in-person & virtual

Register as Delegate →

Attend without presenting.